Stereotaxis, Inc. (STXS) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon. Thank you for joining us for STAIR Tax's third quarter 2025 earnings conference call. Certain statements during the conference call and question and answer period to follow may relate to future events, expectations, and as such constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks uncertainties, and other factors which may cause the actual results, performance, or achievements of a company in the future to be materially different from the statements that the company's executives may make today. These risks are described in detail in our public filings within the Securities and Exchange Commission, including our latest periodic report on Form 10-K or 10-Q. We assume no duty to update these statements. At this time, all participants have been placed on a listen-only mode. The floor will be open for questions and comments following the presentation. As a reminder, today's call is being recorded. It is now my pleasure to turn the floor over to your host, David Fishel, Chairman and CEO of Stereotaxis. Thank you, Operator, and good afternoon, everyone. We are in an exciting period with a lot of progress on multiple fronts. We've discussed our strategy and efforts more comprehensively on previous calls, so I'll keep today's remarks focused on a few key commercial and innovation updates. Our commercial activity can be viewed as two primary efforts. First, to scale robotic system sales with continued adoption of Genesys and the initial launch of GenesysX. And second, to build a robust, high-margin recurring revenue business with our portfolio of novel catheters. These two efforts are independent but obviously synergistic and together support an attractiv...